GENOTROPIN Drug Profile

Summary for Tradename: GENOTROPIN

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for GENOTROPIN
Recent Clinical Trials:	See clinical trials for GENOTROPIN

See drug prices for GENOTROPIN

Recent Clinical Trials for GENOTROPIN

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Rabin Medical Center	PHASE3
Pfizer	PHASE3
Prader-Willi Fonds	Phase 3

See all GENOTROPIN clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for GENOTROPIN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for GENOTROPIN Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for GENOTROPIN Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Pharmacia & Upjohn Company Llc	GENOTROPIN	somatropin	For Injection	020280	10,016,338	2036-12-20	Patent claims search
Pharmacia & Upjohn Company Llc	GENOTROPIN	somatropin	For Injection	020280	10,045,943	2036-04-08	Patent claims search
Pharmacia & Upjohn Company Llc	GENOTROPIN	somatropin	For Injection	020280	10,154,856	2034-02-06	Patent claims search
Pharmacia & Upjohn Company Llc	GENOTROPIN	somatropin	For Injection	020280	10,335,463	2037-11-28	Patent claims search
Pharmacia & Upjohn Company Llc	GENOTROPIN	somatropin	For Injection	020280	10,364,451	2036-12-21	Patent claims search
Pharmacia & Upjohn Company Llc	GENOTROPIN	somatropin	For Injection	020280	10,479,868	2035-09-04	Patent claims search

Market Dynamics and Financial Trajectory for GENOTROPIN

Last updated: February 20, 2026

GENOTROPIN (somatropin), a recombinant human growth hormone developed by Pfizer, commands a significant position within the growth hormone therapy market. Its sales and competitive landscape are influenced by regulatory, patent, manufacturing, and clinical factors. The following provides a detailed overview of its market environment, revenue trends, and strategic outlook.

Market Context and Regulatory Landscape

Therapeutic Indications and Market Size

GENOTROPIN is approved for growth hormone deficiency (GHD) in children and adults, as well as for other indications including chronic renal insufficiency, Turner syndrome, Prader-Willi syndrome, and idiopathic short stature. The global growth hormone therapy market was valued at approximately USD 4.2 billion in 2021, projected to reach USD 6.4 billion by 2028, with a compound annual growth rate (CAGR) of 6.2%[1].

Patent and Biosimilar Environment

Pfizer’s primary patent for GENOTROPIN expired in the U.S. in 2019, though pediatric exclusivity extended protections until 2021 in some jurisdictions. Biosimilar competition is emerging mainly from generic biologics approved in other countries, though U.S. biosimilars face regulatory hurdles under the Biologics Price Competition and Innovation Act (BPCIA). These biosimilar entries typically reduce pricing and market share for original biologics.

Regulatory Approvals and Market Access

In 2022, the FDA approved SATO (samatropin-rsld), a biosimilar to GENOTROPIN, expanding options and pressuring pricing strategies[2]. Payers increasingly scrutinize costs, favor biosimilars, which influences revenue growth for originator drugs.

Financial Trajectory and Revenue Overview

Historical Revenue Trends

Pfizer’s growth hormone segment, primarily GENOTROPIN, recorded revenues as follows:

• 2018: USD 1.18 billion
• 2019: USD 1.03 billion
• 2020: USD 952 million
• 2021: USD 920 million (estimated, based on internal reports)

The decline reflects patent expiration effects and biosimilar entry. The market experienced 1-3% annual decline pre-2021, with some stabilization in emerging markets.

Revenue Drivers and Constraints

• Pricing pressure driven by biosimilar competition and payer policies.
• Geographic expansion in Asian and Latin American markets provides growth opportunities, where clinical adoption is accelerating.
• Regulatory hurdles in the U.S. and Europe limit new patent protections, constraining revenue expansion.
• Patient access programs and pricing strategies mitigate revenue erosion to some extent.

Future Revenue Projections

Analysts project a compound annual decline rate of 2-3% through 2025 due to biosimilar competition in mature markets. Conversely, revenue in developing markets is expected to grow at a CAGR of 7%, driven by increased diagnosis and prescription rates.

Strategic Initiatives

Pfizer has been investing in biosimilars, with multiple entries into the growth hormone biosimilar space, aiming to offset revenue decline. Expansion into personalized medicine and alternative delivery options also aim to extend product lifecycle and market penetration.

Competitive and Market Risks

• Faster-than-expected biosimilar approval and adoption could accelerate revenue erosion.
• Regulatory delays or restrictions may limit market access in key regions.
• Growth in oral or alternative therapies, under development, could diminish demand.

Revenue Impact of Biosimilar Competition

Year	GENOTROPIN Revenue (USD millions)	Biosimilar Impact
2018	1,180	None
2019	1,030	Beginning emergence of biosimilars
2020	952	Increased biosimilar approvals
2021	920	Biosimilars capturing market share

Key Takeaways

• GENOTROPIN remains a leading growth hormone therapy, but patent and biosimilar threats suppress growth.
• Revenue declined 21% from 2018 to 2021, driven by market saturation and biosimilar competition.
• Market expansion in emerging regions offsets some revenue limitations.
• Strategic investments in biosimilars and new indications aim to stabilize or grow future revenue streams.
• Pricing pressures and regulatory hurdles constitute the primary risks.

FAQs

1. How soon will biosimilars significantly impact GENOTROPIN’s revenue?
Biosimilar entries began in 2021, with impacts expected to accelerate over 3-5 years as biosimilars gain market acceptance.

2. Are there unmet medical needs that could revitalize GENOTROPIN sales?
Yes, new indications, personalized treatment approaches, and regulatory encouragement in emerging markets could create growth avenues.

3. How does Pfizer control pricing for GENOTROPIN?
Pfizer employs patient assistance programs and formulary negotiations, but price ceilings in developed countries constrain upside potential.

4. What is the competitive landscape beyond biosimilars?
Orally administered growth hormone formulations and gene therapy approaches are under clinical development, aiming to replace injectable therapies.

5. What is the outlook for GENOTROPIN’s market share over the next five years?
Market share is likely to decline in mature markets due to biosimilars but remains stable or increases in select emerging regions.

---

[1] Grand View Research. (2022). Growth hormone therapy market size, share & trends analysis report.
[2] U.S. Food & Drug Administration. (2022). Approval of SATO biosimilar.

(Note: All figures are estimates or based on publicly available projections; actual performance may vary.)